Compare CVE & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | IDXX |
|---|---|---|
| Founded | 2009 | 1983 |
| Country | Canada | United States |
| Employees | 8300 | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0B | 43.6B |
| IPO Year | N/A | 1996 |
| Metric | CVE | IDXX |
|---|---|---|
| Price | $24.81 | $551.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $30.50 | ★ $721.67 |
| AVG Volume (30 Days) | ★ 8.3M | 587.1K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 22.59 |
| EPS | N/A | ★ 3.47 |
| Revenue | N/A | ★ $4,303,702,000.00 |
| Revenue This Year | N/A | $10.88 |
| Revenue Next Year | $2.74 | $8.59 |
| P/E Ratio | ★ $18.07 | $159.95 |
| Revenue Growth | N/A | ★ 10.42 |
| 52 Week Low | $13.47 | $507.55 |
| 52 Week High | $32.07 | $769.98 |
| Indicator | CVE | IDXX |
|---|---|---|
| Relative Strength Index (RSI) | 33.72 | 47.27 |
| Support Level | $24.22 | $549.60 |
| Resistance Level | $30.47 | $587.04 |
| Average True Range (ATR) | 0.76 | 16.94 |
| MACD | -0.35 | -1.19 |
| Stochastic Oscillator | 8.45 | 29.24 |
Cenovus Energy Inc is a Canadian integrated energy group. The group's upstream operations include oil sands projects in northern Alberta; thermal and conventional crude oil, natural gas, and natural gas liquids (NGLs) projects across Western Canada; crude oil production offshore Newfoundland and Labrador; and natural gas and NGLs production offshore China and Indonesia. Its downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada. The group's reportable segments are: Oil Sands, Conventional, Offshore, Canadian Refining, U.S Refining, and Corporate and Eliminations. Maximum revenue is generated from its Oil Sands segment. Geographically, the group derives maximum revenue from the U.S., followed by Canada and China.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.